- IBDEI367 ; ; 04-FEB-2020
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,50623,2)
- ;;=^5001814
- ;;^UTILITY(U,$J,358.3,50624,0)
- ;;=C92.A0^^193^2497^12
- ;;^UTILITY(U,$J,358.3,50624,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50624,1,3,0)
- ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
- ;;^UTILITY(U,$J,358.3,50624,1,4,0)
- ;;=4^C92.A0
- ;;^UTILITY(U,$J,358.3,50624,2)
- ;;=^5001813
- ;;^UTILITY(U,$J,358.3,50625,0)
- ;;=C92.51^^193^2497^13
- ;;^UTILITY(U,$J,358.3,50625,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50625,1,3,0)
- ;;=3^Acute Myelomonocytic Leukemia,In Remission
- ;;^UTILITY(U,$J,358.3,50625,1,4,0)
- ;;=4^C92.51
- ;;^UTILITY(U,$J,358.3,50625,2)
- ;;=^5001805
- ;;^UTILITY(U,$J,358.3,50626,0)
- ;;=C92.50^^193^2497^14
- ;;^UTILITY(U,$J,358.3,50626,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50626,1,3,0)
- ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
- ;;^UTILITY(U,$J,358.3,50626,1,4,0)
- ;;=4^C92.50
- ;;^UTILITY(U,$J,358.3,50626,2)
- ;;=^5001804
- ;;^UTILITY(U,$J,358.3,50627,0)
- ;;=C94.40^^193^2497^17
- ;;^UTILITY(U,$J,358.3,50627,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50627,1,3,0)
- ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
- ;;^UTILITY(U,$J,358.3,50627,1,4,0)
- ;;=4^C94.40
- ;;^UTILITY(U,$J,358.3,50627,2)
- ;;=^5001843
- ;;^UTILITY(U,$J,358.3,50628,0)
- ;;=C94.42^^193^2497^15
- ;;^UTILITY(U,$J,358.3,50628,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50628,1,3,0)
- ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
- ;;^UTILITY(U,$J,358.3,50628,1,4,0)
- ;;=4^C94.42
- ;;^UTILITY(U,$J,358.3,50628,2)
- ;;=^5001845
- ;;^UTILITY(U,$J,358.3,50629,0)
- ;;=C94.41^^193^2497^16
- ;;^UTILITY(U,$J,358.3,50629,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50629,1,3,0)
- ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
- ;;^UTILITY(U,$J,358.3,50629,1,4,0)
- ;;=4^C94.41
- ;;^UTILITY(U,$J,358.3,50629,2)
- ;;=^5001844
- ;;^UTILITY(U,$J,358.3,50630,0)
- ;;=D62.^^193^2497^18
- ;;^UTILITY(U,$J,358.3,50630,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50630,1,3,0)
- ;;=3^Acute Posthemorrhagic Anemia
- ;;^UTILITY(U,$J,358.3,50630,1,4,0)
- ;;=4^D62.
- ;;^UTILITY(U,$J,358.3,50630,2)
- ;;=^267986
- ;;^UTILITY(U,$J,358.3,50631,0)
- ;;=C92.41^^193^2497^19
- ;;^UTILITY(U,$J,358.3,50631,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50631,1,3,0)
- ;;=3^Acute Promyelocytic Leukemia,In Remission
- ;;^UTILITY(U,$J,358.3,50631,1,4,0)
- ;;=4^C92.41
- ;;^UTILITY(U,$J,358.3,50631,2)
- ;;=^5001802
- ;;^UTILITY(U,$J,358.3,50632,0)
- ;;=C92.40^^193^2497^20
- ;;^UTILITY(U,$J,358.3,50632,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50632,1,3,0)
- ;;=3^Acute Promyelocytic Leukemia,Not in Remission
- ;;^UTILITY(U,$J,358.3,50632,1,4,0)
- ;;=4^C92.40
- ;;^UTILITY(U,$J,358.3,50632,2)
- ;;=^5001801
- ;;^UTILITY(U,$J,358.3,50633,0)
- ;;=D56.0^^193^2497^21
- ;;^UTILITY(U,$J,358.3,50633,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50633,1,3,0)
- ;;=3^Alpha Thalassemia
- ;;^UTILITY(U,$J,358.3,50633,1,4,0)
- ;;=4^D56.0
- ;;^UTILITY(U,$J,358.3,50633,2)
- ;;=^340494
- ;;^UTILITY(U,$J,358.3,50634,0)
- ;;=D63.1^^193^2497^23
- ;;^UTILITY(U,$J,358.3,50634,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50634,1,3,0)
- ;;=3^Anemia in Chronic Kidney Disease
- ;;^UTILITY(U,$J,358.3,50634,1,4,0)
- ;;=4^D63.1
- ;;^UTILITY(U,$J,358.3,50634,2)
- ;;=^332908
- ;;^UTILITY(U,$J,358.3,50635,0)
- ;;=D63.0^^193^2497^24
- ;;^UTILITY(U,$J,358.3,50635,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,50635,1,3,0)
- ;;=3^Anemia in Neoplastic Disease
- ;;^UTILITY(U,$J,358.3,50635,1,4,0)
- ;;=4^D63.0
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI367 3786 printed Feb 19, 2025@00:09:01 Page 2
- IBDEI367 ; ; 04-FEB-2020
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,50623,2)
- +2 ;;=^5001814
- +3 ;;^UTILITY(U,$J,358.3,50624,0)
- +4 ;;=C92.A0^^193^2497^12
- +5 ;;^UTILITY(U,$J,358.3,50624,1,0)
- +6 ;;=^358.31IA^4^2
- +7 ;;^UTILITY(U,$J,358.3,50624,1,3,0)
- +8 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
- +9 ;;^UTILITY(U,$J,358.3,50624,1,4,0)
- +10 ;;=4^C92.A0
- +11 ;;^UTILITY(U,$J,358.3,50624,2)
- +12 ;;=^5001813
- +13 ;;^UTILITY(U,$J,358.3,50625,0)
- +14 ;;=C92.51^^193^2497^13
- +15 ;;^UTILITY(U,$J,358.3,50625,1,0)
- +16 ;;=^358.31IA^4^2
- +17 ;;^UTILITY(U,$J,358.3,50625,1,3,0)
- +18 ;;=3^Acute Myelomonocytic Leukemia,In Remission
- +19 ;;^UTILITY(U,$J,358.3,50625,1,4,0)
- +20 ;;=4^C92.51
- +21 ;;^UTILITY(U,$J,358.3,50625,2)
- +22 ;;=^5001805
- +23 ;;^UTILITY(U,$J,358.3,50626,0)
- +24 ;;=C92.50^^193^2497^14
- +25 ;;^UTILITY(U,$J,358.3,50626,1,0)
- +26 ;;=^358.31IA^4^2
- +27 ;;^UTILITY(U,$J,358.3,50626,1,3,0)
- +28 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
- +29 ;;^UTILITY(U,$J,358.3,50626,1,4,0)
- +30 ;;=4^C92.50
- +31 ;;^UTILITY(U,$J,358.3,50626,2)
- +32 ;;=^5001804
- +33 ;;^UTILITY(U,$J,358.3,50627,0)
- +34 ;;=C94.40^^193^2497^17
- +35 ;;^UTILITY(U,$J,358.3,50627,1,0)
- +36 ;;=^358.31IA^4^2
- +37 ;;^UTILITY(U,$J,358.3,50627,1,3,0)
- +38 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
- +39 ;;^UTILITY(U,$J,358.3,50627,1,4,0)
- +40 ;;=4^C94.40
- +41 ;;^UTILITY(U,$J,358.3,50627,2)
- +42 ;;=^5001843
- +43 ;;^UTILITY(U,$J,358.3,50628,0)
- +44 ;;=C94.42^^193^2497^15
- +45 ;;^UTILITY(U,$J,358.3,50628,1,0)
- +46 ;;=^358.31IA^4^2
- +47 ;;^UTILITY(U,$J,358.3,50628,1,3,0)
- +48 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
- +49 ;;^UTILITY(U,$J,358.3,50628,1,4,0)
- +50 ;;=4^C94.42
- +51 ;;^UTILITY(U,$J,358.3,50628,2)
- +52 ;;=^5001845
- +53 ;;^UTILITY(U,$J,358.3,50629,0)
- +54 ;;=C94.41^^193^2497^16
- +55 ;;^UTILITY(U,$J,358.3,50629,1,0)
- +56 ;;=^358.31IA^4^2
- +57 ;;^UTILITY(U,$J,358.3,50629,1,3,0)
- +58 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
- +59 ;;^UTILITY(U,$J,358.3,50629,1,4,0)
- +60 ;;=4^C94.41
- +61 ;;^UTILITY(U,$J,358.3,50629,2)
- +62 ;;=^5001844
- +63 ;;^UTILITY(U,$J,358.3,50630,0)
- +64 ;;=D62.^^193^2497^18
- +65 ;;^UTILITY(U,$J,358.3,50630,1,0)
- +66 ;;=^358.31IA^4^2
- +67 ;;^UTILITY(U,$J,358.3,50630,1,3,0)
- +68 ;;=3^Acute Posthemorrhagic Anemia
- +69 ;;^UTILITY(U,$J,358.3,50630,1,4,0)
- +70 ;;=4^D62.
- +71 ;;^UTILITY(U,$J,358.3,50630,2)
- +72 ;;=^267986
- +73 ;;^UTILITY(U,$J,358.3,50631,0)
- +74 ;;=C92.41^^193^2497^19
- +75 ;;^UTILITY(U,$J,358.3,50631,1,0)
- +76 ;;=^358.31IA^4^2
- +77 ;;^UTILITY(U,$J,358.3,50631,1,3,0)
- +78 ;;=3^Acute Promyelocytic Leukemia,In Remission
- +79 ;;^UTILITY(U,$J,358.3,50631,1,4,0)
- +80 ;;=4^C92.41
- +81 ;;^UTILITY(U,$J,358.3,50631,2)
- +82 ;;=^5001802
- +83 ;;^UTILITY(U,$J,358.3,50632,0)
- +84 ;;=C92.40^^193^2497^20
- +85 ;;^UTILITY(U,$J,358.3,50632,1,0)
- +86 ;;=^358.31IA^4^2
- +87 ;;^UTILITY(U,$J,358.3,50632,1,3,0)
- +88 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
- +89 ;;^UTILITY(U,$J,358.3,50632,1,4,0)
- +90 ;;=4^C92.40
- +91 ;;^UTILITY(U,$J,358.3,50632,2)
- +92 ;;=^5001801
- +93 ;;^UTILITY(U,$J,358.3,50633,0)
- +94 ;;=D56.0^^193^2497^21
- +95 ;;^UTILITY(U,$J,358.3,50633,1,0)
- +96 ;;=^358.31IA^4^2
- +97 ;;^UTILITY(U,$J,358.3,50633,1,3,0)
- +98 ;;=3^Alpha Thalassemia
- +99 ;;^UTILITY(U,$J,358.3,50633,1,4,0)
- +100 ;;=4^D56.0
- +101 ;;^UTILITY(U,$J,358.3,50633,2)
- +102 ;;=^340494
- +103 ;;^UTILITY(U,$J,358.3,50634,0)
- +104 ;;=D63.1^^193^2497^23
- +105 ;;^UTILITY(U,$J,358.3,50634,1,0)
- +106 ;;=^358.31IA^4^2
- +107 ;;^UTILITY(U,$J,358.3,50634,1,3,0)
- +108 ;;=3^Anemia in Chronic Kidney Disease
- +109 ;;^UTILITY(U,$J,358.3,50634,1,4,0)
- +110 ;;=4^D63.1
- +111 ;;^UTILITY(U,$J,358.3,50634,2)
- +112 ;;=^332908
- +113 ;;^UTILITY(U,$J,358.3,50635,0)
- +114 ;;=D63.0^^193^2497^24
- +115 ;;^UTILITY(U,$J,358.3,50635,1,0)
- +116 ;;=^358.31IA^4^2
- +117 ;;^UTILITY(U,$J,358.3,50635,1,3,0)
- +118 ;;=3^Anemia in Neoplastic Disease
- +119 ;;^UTILITY(U,$J,358.3,50635,1,4,0)
- +120 ;;=4^D63.0